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Abstract 
Objectives: Prostate-specific-antigen (PSA) screening resulted in reduced prostate 
cancer (PCa) mortality in a large clinical trial, but due to many false positives and 
overdiagnosis of indolent disease, many guidelines do not endorse universal screening 
and instead recommend an individualized decision based on each patient’s risk. We 
sought to develop and validate a genetic tool to predict age of aggressive PCa onset 
and to guide decisions of whom to screen and at what age. 
Design: Genotype, PCa status, and age were analyzed to select single-nucleotide 
polymorphisms (SNPs) associated with PCa diagnosis. These SNPs were incorporated 
into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa 
(i.e., not eligible for surveillance per NCCN Guidelines; any of: Gleason score ≥7, stage 
T3-T4, PSA ≥10, nodal metastasis, distant metastasis). The resulting polygenic hazard 
score (PHS) is an assessment of individual genetic risk. The final model was applied to 
an independent dataset containing genotype and screening PSA data. PHS was 
calculated for these men to test prediction of PCa-free survival.  
Setting: Multiple, international PRACTICAL consortium member institutions. 
Participants: All PRACTICAL consortium participants of European ancestry with known 
age, PCa status, and quality-assured iCOGS array genotype data. Development 
dataset comprised 31,747 men. Validation dataset comprised 6,411 men.  
Main outcome measures: PHS prediction of age of onset of aggressive PCa in 
validation set.  
Results: In the independent validation set, PHS calculated from 54 SNPs was a highly 
significant predictor of age at diagnosis of aggressive PCa (z=11.2, p<10-16). When men 
in the validation set with high PHS (>98th percentile) were compared to those with 
average PHS (30th-70th percentile), the hazard ratio for aggressive PCa was 2.9.  
Conclusions: Polygenic hazard scores give personalized genetic risk estimates that 
predict for age of onset of aggressive PCa.  
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What this paper adds (box) 
 
What is already known on this subject  
 Prostate cancer (PCa) screening with prostate-specific-antigen (PSA) testing can 
lead to early detection of PCa and allow for curative treatment, but universal 
screening also has considerable disadvantages for men who may never develop 
aggressive disease. 
 Ideally, physicians would identify and screen patients at high risk of developing 
aggressive PCa or PCa at a young age. 
 A practical, clinically useful tool to predict age of PCa onset is not yet available. 
 
What this study adds  
 This study presents and validates a novel polygenic hazard score (PHS) that is 
an indicator of age of onset of aggressive PCa. 
 PHS is a relatively inexpensive assessment of an individual man’s age-specific 
PCa risk and provides objective information on whether a given patient might 
benefit from PSA screening. 
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Introduction 
Prostate cancer (PCa) is a major health problem, with over one million new cases and 
over 300,000 PCa deaths estimated worldwide in 20121. An international, randomized, 
controlled trial showed that prostate-specific-antigen (PSA) screening resulted in a 27% 
reduction in PCa mortality2. However, due to concerns over a high rate of false 
positives, in addition to aggressive treatment of apparently indolent disease, many 
clinical guidelines do not endorse universal screening and instead stress the importance 
of taking into account individual patient risk factors to decide whether to screen3–5. The 
goal is to avoid unnecessary screening while still identifying high-risk men for whom 
screening and early PCa detection can reduce morbidity and mortality.  
A patient’s genetic predisposition could be critical to the decision of whether and when 
to offer him PCa screening. Genome-wide association studies (GWAS) have revealed 
genetic variants associated with increased risk of PCa6,7. These developments, 
combined with the recent accessibility of genotyping, provide an opportunity for genetic 
risk-informed cancer screening8. By combining risk information from an array of single-
nucleotide polymorphisms (SNPs), polygenic models can estimate an individual’s 
genetic risk for developing the disease9. Predicted polygenic risk could improve clinical 
decisions such as whom to screen for PCa and at what age10,11.  
Here we use data from 31,747 men of European ancestry from the international 
PRACTICAL consortium (http://practical.ccge.medschl.cam.ac.uk/) to develop a 
polygenic hazard score (PHS) for predicting age-related risk of developing aggressive 
PCa. This is designed for use before the decision of whether to screen (e.g., with PSA) 
by providing a risk stratification strategy to maximize screening efficiency. The PHS was 
therefore tested in data from an independent, screening study (UK ProtecT12), with the 
hypothesis that PHS would be an indicator of a patient’s inherent genetic risk for 
developing PCa at various ages in his lifetime, and thus could guide PSA screening. 
 
Methods 
Definition of aggressive disease 
Concerns about overdiagnosis and overtreatment of indolent disease have influenced 
discussion of PCa screening, whereas there is consensus that aggressive PCa warrants 
treatment13,14. Where possible, we therefore focus validation in this study on prediction 
of aggressive disease, defined as any tumor that would require radical treatment for a 
typical, healthy man according to National Comprehensive Cancer Network (NCCN) 
Guidelines (i.e., not eligible for active surveillance)14. This includes cancers with any of: 
Gleason score ≥7, stage T3-T4, PSA ≥10, nodal metastasis, or distant metastasis. Note 
that stage T2 tumors were classified without a sub-category in our database, so a 
patient with low Gleason score and low PSA, but stage T2b or T2c would be considered 
low risk in this analysis even though NCCN Guidelines would indicate treatment for 
intermediate risk; this was to ensure that no low-risk tumors were included as cases of 
aggressive PCa.  
Some additional analyses used age of diagnosis of any PCa, either as complementary 
information or because available data did not permit exclusive focus on aggressive 
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PCa. This is noted, where applicable. Another secondary analysis tested prediction for 
‘very aggressive disease,’ defined as any of: Gleason score ≥8, stage T3-4, positive 
nodes, or distant metastases. 
 
Participants  
Development Set: For PHS model development, genotype and age data were obtained 
from 21 studies of the PRACTICAL consortium (Supplementary Table S1), representing 
31,747 men (18,868 any PCa, 10,635 aggressive PCa, 5,406 very aggressive 
PCa,12,879 controls) of genotypic European ancestry. Age was either at PCa diagnosis 
or last follow-up (for controls). Genotyping, performed via a custom Illumina array 
(iCOGS), and quality control steps have been described previously6. 201,043 SNPs 
were available for analysis. Categorization as aggressive or not was impossible for 
4,803 of the PCa cases due to incomplete staging data; these were excluded from 
aggressive PCa analyses.  
Validation Set: Model performance was examined in an independent study. The 
Validation Set comes from the ProtecT study, which screened 82,429 men with PSA 
testing and found 8,891 men with PSA greater than the specified threshold of 3.0 g/L 
or higher, of whom 2,896 were diagnosed with PCa12. Among those individuals, we 
obtained genotype and age data for 6,411 men (1,583 any PCa, 632 aggressive PCa, 
220 very aggressive PCa, 4,828 controls). Staging data were available for all cases. 
This dataset was selected for validation because PSA results were also available for all 
participants at time of either diagnosis or interview. Further details in Supplementary 
Methods. 
 
Missing data: 
During model development, SNPs with call rates less than 95% were excluded. Missing 
calls for the remaining SNPs were imputed with the mean genotype count for that allele 
across all participants. 
 
Polygenic hazard score (PHS) 
The polygenic hazard score (PHS) was developed previously as a parsimonious, 
survival-analysis model to predict the time to event outcome (in this case, age of PCa 
onset). It has been published elsewhere15, and further details of application here are 
described in Supplementary Material.  
The polygenic hazard score (PHS) is defined as the vector product of a patient’s 
genotype (Xi) for n selected SNPs and the corresponding parameter estimates (𝛽i) from 
a Cox proportional hazards regression:  
𝑃𝐻𝑆𝑋 =  ∑ 𝑋𝑖𝛽𝑖
𝑛
𝑖
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Genetic prediction of only aggressive PCa has proven elusive, with most SNPs 
associated with aggressive disease also showing association with any PCa16. 
Therefore, in the interest of maximizing power to select SNPs associated with age of 
onset of PCa, we decided to initially include all cases from the Development Set (i.e., 
any PCa) for generation of the PHS model. An alternate strategy that limited model 
generation to aggressive PCa cases was then tested for comparison. The primary 
metric for validation in both instances remained prediction for aggressive PCa in the 
independent Validation Set. 
To verify whether the PHS accurately predicts age of aggressive PCa onset, the PHS 
was calculated for all patients in the Validation Set and tested as the sole predictive 
variable in a Cox proportional hazards regression model for age of diagnosis. Patients 
in the Validation Set diagnosed with low-risk PCa (Gleason score <=6, PSA<10, and 
stage T2N0M0 or lower) were censored at time of diagnosis, reflecting the fact that it is 
unknown if they would later be diagnosed with aggressive disease or at what age that 
might have occurred. Statistical significance was set at alpha of 0.01 for this and all 
subsequent Cox models. As an indicator of effect size for the model, we calculated a 
hazard ratio comparing men with high PHS (>98th percentile) to those with average risk 
(30th-70th percentile). All hazard ratios in this manuscript refer to the same pattern, 
comparing high to average risk. 
In light of evidence that initially low-risk disease often progresses to require treatment17–
19, and because this may be particularly important for men diagnosed at a young age, 
we performed a secondary, analogous analysis to test for prediction of age of diagnosis 
of any PCa. Another secondary analysis was done for prediction of very aggressive 
disease. 
  
To further assess the clinical significance of PHS, we looked at the positive predictive 
value (PPV) of PSA testing within the Validation Set, with clinical diagnosis (including 
biopsy result) as the gold standard. We posited that risk stratification by PHS 
percentiles would reflect the underlying incidence of PCa and therefore also affect the 
PPV of PSA testing. Details of PPV calculation are in the Supplementary Material. PHS 
categories were designated by PHS percentile compared to the young, healthy 
population within the Development Set: i.e., those controls with age <70 years. All 
percentiles reported in this manuscript refer to this population.  
To visualize PHS distribution among aggressive PCa cases in the Validation Set, we 
generated a Lorenz curve20–22. 
 
Comparison to family history 
One of the most important risk factors used currently for screening decisions is family 
history3. We compared family history and PHS for prediction of aggressive PCa onset 
using the same Cox model approach as before, using the 5,703 men (1,405 any PCa, 
554 aggressive PCa, 4,298 controls) from the Validation Set with known family history 
status (0 or ≥1 affected first-degree relatives). Models were constructed with family 
history alone, PHS alone, or with both. These were compared via log-likelihood tests.  
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Results 
PHS model development 
Of the 201,043 SNPs included in the dataset, 2,415 were associated with increased risk 
of PCa in the trend test, with p<10-6. The stepwise regression framework then identified 
54 of these SNPs that were incorporated into the Cox proportional hazards model 
(Supplementary Table S2). The 54 SNP parameter estimates (for the hazard of 
developing PCa) are combined with individual genotype to generate the polygenic 
hazard score. Kaplan-Meier and Cox regression estimates for the final model are shown 
in Figure 1. The final model performed well for prediction of age of aggressive PCa 
onset in the Development Set (z=37.5, p<10-16, HR=2.3 [95% CI: 2.2, 2.4]).  
Only 43 SNPs (0.02%) were excluded for low call rate during model development, and 
imputation for missing calls was used for 0.4% of calls in the final model. Of the 6,411 
participants in the Validation Set, the median individual SNP call rate was 100%, with a 
minimum of 98%.  
 
PCa risk prediction with PHS 
In the independent Validation Set from the ProtecT study, a Cox proportional hazards 
model showed that PHS was a significant predictor of age of onset of aggressive PCa 
(z=11.2, p<10-16). The hazard ratio for high PHS men (>98th percentile) compared to 
average risk was 2.9 [95% CI: 2.4, 3.4]. PHS was also predictive of any PCa (z=15.4, 
p<10-16, HR=2.5 [2.2, 2.8]) and very aggressive PCa (z=6.8, p<10-11, HR=3.0 [2.2, 4.0]). 
An alternate model used only aggressive PCa cases from the Development Set to 
select SNPs. Prediction for aggressive PCa onset was still significant (z=9.4, p<10-16, 
HR=2.6 [2.1, 3.1]) but did not outperform the original model, so the original was used for 
all subsequent analyses as planned. 
As PHS is predictive of PCa risk, we expected PHS to modulate the positive predictive 
value (PPV) of PSA testing in the Validation Set. Indeed, PPV of PSA was lower among 
patients with a low PHS, and higher among patients with progressively higher PHS 
(Figure 2). This pattern held for PPV for any PCa, as well (Supplementary Figure S2). 
The distribution of PHS among aggressive PCa cases in the Validation Set is shown as 
a Lorenz curve in Supplementary Figure S3. Patients with PHS above the 50th 
percentile accounted for 76% of aggressive PCa, and the upper quintile accounted for 
42% of aggressive PCa. 
 
Family History 
Using the subset of the Validation Set with known family history status (1,405 cases, 
4,298 controls), the Cox test was repeated while accounting for family history. Family 
history alone was not predictive of age of onset of aggressive PCa (z=0.9, p=0.37, 
HR=1.1 [0.9, 1.4]), though there was a trend toward prediction for any PCa (z=2.0, 
p=0.05, HR=1.2 [1.0, 1.3]). Including family history did not improve prediction over PHS 
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alone for aggressive PCa (p=0.59) or any PCa (p=0.14), and PHS remained predictive 
when accounting for family history. 
 
Discussion 
PCa risk prediction with PHS 
Genetic information may guide the decision of whether an individual patient needs PCa 
screening8. The PHS described here represents a personalized genetic assessment of 
a patient’s age-related PCa risk that could inform both whether and when to order 
screening tests. When applied to data from an independent clinical trial, PHS was a 
highly significant predictor of age at diagnosis of aggressive PCa. Men in the top 2% of 
PHS had a hazard ratio of 2.9 for aggressive PCa compared to men with average risk. 
As PHS is representative of a man’s fixed genetic risk, it can be calculated once, long 
before onset of PCa, and substantially inform the decision of whether he should 
undergo PCa screening.  
PPV is directly dependent on prevalence, so if PHS predicts age of PCa onset, the PPV 
of PSA should vary with PHS. Figure 2 shows that this was true in the Validation Set. 
Nearly a quarter of the positive PSA tests in high PHS patients portended a diagnosis of 
aggressive PCa. The risk was much lower for low-PHS patients with elevated PSA. 
PHS is an indicator of the utility of PSA screening and could be influential when 
deciding whether to order a PSA test for a given patient.  
These results also add to existing data as further evidence that genetic features are 
predictive of PCa risk6–8,11,23–25. Investigation into the genotypic features described here 
and elsewhere may give additional insight into biological rationales for the association 
with PCa. 
PHS is based on hazard ratios and is therefore a relative estimate of risk. Absolute risk 
can be estimated within a given population if the underlying average hazard rate is 
known. This technique would then allow estimation of an individual PCa-free survival 
curve for any PHS. An example of these individual curves has been published for 
Alzheimer’s disease15. 
 
Comparison with family history 
Family history of PCa is one of the most commonly used risk factors in clinic to 
determine screening decisions3. However, family history was not predictive of age of 
onset of aggressive PCa in the Validation Set, and it did not improve prediction over 
PHS alone. This may reflect a lack of power to detect an association for family history in 
the relatively small Validation Set. 
 
Concern of overtreatment 
A concern with PSA screening is overdiagnosis and overtreatment of indolent disease. 
As with other genetic prediction tools, PHS is not specific for only aggressive PCa,16 
though the PHS hazard ratio was slightly higher for aggressive PCa than for any PCa. 
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The problem of overdiagnosis is compounded by the observation that many patients 
initially diagnosed with low-risk disease are later diagnosed with aggressive 
disease19,17. Active surveillance is one answer to overtreatment that avoids up-front 
treatment but still allows monitoring for development of indications that treatment is 
necessary. Indeed, most tumors eventually require treatment17,18, and earlier treatment 
prevents development of metastatic disease18. Hence, avoiding screening altogether in 
patients who may develop PCa at a young age does carry risk of considerable 
morbidity. The present results show that PHS can help target screening efforts toward 
those men at highest risk of early-onset PCa or aggressive PCa requiring treatment. 
Since PHS is predictive of aggressive PCa in general, it might also be useful for 
predicting outcomes of men diagnosed with low-risk PCa in ProtecT. The clinical data 
necessary to answer this interesting question have not yet been made available to the 
PRACTICAL consortium, so it will have to be explored in future analyses.  
 
Previous tools 
Prior studies have used GWAS-associated polymorphisms to predict risk of PCa using a 
case/control design23–25. However, epidemiologic data show that PCa risk is not a 
simple dichotomy of cases and controls, but rather is highly dependent on increasing 
age. Therefore, we opted for a survival analysis approach optimized for genetic 
prediction of age of PCa onset. The PHS can then be used in clinical decisions, where 
age plays a critical role. If a man has a high risk of developing PCa at age 95, this is a 
very different clinical situation from a man at high risk at age 55. A comparison of PHS 
with a traditional polygenic risk score (PRS) is described in the Supplementary Material. 
Other PCa risk calculators use clinical variables and are most useful for a man who may 
already have PCa26–28. PSA is often included, meaning the decision of whether to 
screen has necessarily already been made when the tools are to be used. These are 
less useful for predicting his lifetime risk before he reaches an age where he and his 
physician have to decide whether he should follow some program of PCa screening.  
The risk-stratification metric with best supportive evidence described in the literature is 
an early midlife PSA level measured at a relatively young age (e.g., <50 years). While 
not currently recommended in many major clinical guidelines3–5, early midlife PSA has 
been shown to be predictive of future risk of PCa and lethal PCa22,29–31. One nested 
case-control study showed that just the top 10% of early PSA accounted for 40% of 
metastatic PCa cases22. This has led to a recommendation to consider PSA testing as 
early as age 45 in men thought by their physician to be at high risk of PCa32. A direct 
comparison of PHS and early midlife PSA for prediction of age of onset of aggressive 
PCa would be worthwhile. There may also be an advantage to combining the two 
predictors. Unfortunately, early midlife PSA is not available here, so the question is left 
for future work.  
 
Limitations 
The Development Set is a heterogeneous composite of several studies of varied design 
(Supplemental Table S1), which provides sufficient power to study SNPs with relatively 
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small effect sizes but also raises the concern of undetected bias in a retrospective 
analysis. However, the Validation Set comes from an independent, large, prospective 
trial, and whatever problems might exist in the Development Set, the most pertinent 
question is whether the model allows useful predictions.  
PHS was applied here to PSA screening alone. PSA is the most prevalent screening 
test currently for PCa, but PHS could be expected to add value to other screening 
strategies, too, by predicting underlying risk of PCa for a given age and therefore 
influencing pre-test probability (and, by extension, PPV). This might include PSA 
velocity, PSA density, or some screening tool completely independent of PSA. 
The evidence presented here suggests PHS can help a physician decide whether to 
order PSA, based on the pre-test probability and PPV of PSA for a given patient. 
However, this study does not address an alternate question: how PHS might compare 
to diagnostic tools (including risk calculators) that are part of the clinical work-up after 
an elevated PSA has been found. Adequate data are not available in the present 
dataset to answer this question, but it could be tried in future work as an additional 
application of PHS. 
The age range of the Validation Set is limited to only 50-70 years; fortunately, this 
includes the age where screening is believed to have the most benefit33–36.  
Finally, ethnicity in this PHS model is limited to European ancestry. Validation of PHS in 
other ethnic groups—and, if necessary, custom models for each—is needed. Our group 
plans to investigate this important question.    
 
Conclusions                                                                                                                                                                      
In conclusion, we describe here the development of a new polygenic hazard score 
(PHS) for personalized genetic assessment of individual, age-associated PCa risk. This 
score has been validated in an independent dataset, demonstrating accurate prediction 
of aggressive PCa onset. Moreover, PHS is shown to predict the utility of PSA testing 
for an individual patient. This genetic risk model might play a role in guiding decisions 
about whether and when to screen for PCa. Investigation into the relationship of PHS 
and early midlife PSA is warranted. 
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Figures 
 
 
 
 
Figure 1: Kaplan-Meier estimates of prostate cancer-free survival for patients in the 
Development Set, grouped by PHS percentile ranges (as shown in the legend). Cox 
regression estimates for the same groups are shown as dotted lines of corresponding 
color. PHS percentiles are in reference to the distribution of PHS within the 11,190 
controls in the Development Set who were under 70 years old. Time of “failure” is age at 
any prostate cancer diagnosis. Controls were censored at age of observation. Formal 
testing of proportionality is described in the Supplementary Material. 
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Figure 2: Positive predictive value (PPV) of PSA testing for aggressive PCa in the 
Validation Set. Percentiles refer to the PHS distribution among young controls in the 
Development Set. Colored lines are 95% confidence intervals from random samples of 
cases in the Validation Set (see Methods). 
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